Institutional risk management for out-of-specification commercial CAR-T products

Bone Marrow Transplantation · Published 2026-07-21 · DOI 10.1038/s41409-026-02986-y

Authors (2)

Ron Ram, Ronit R. Gold

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ram, R., Gold, R. (2026). Institutional risk management for out-of-specification commercial CAR-T products. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-026-02986-y

Related articles

• Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT · Bone Marrow Transplantation · 2026 · Same journal
• Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols · Bone Marrow Transplantation · 2026 · Same journal
• Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities · Bone Marrow Transplantation · 2026 · Same journal
• The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P973–P983) · Bone Marrow Transplantation · 2026 · Same journal
• Vaccination in haematopoietic stem cell transplantation and cellular therapies: consensus, divergence, and uncertainties in global practice · Bone Marrow Transplantation · 2026 · Same journal
• CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy · Bone Marrow Transplantation · 2026 · Same journal
• The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards · Bone Marrow Transplantation · 2026 · Same journal
• Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis · Bone Marrow Transplantation · 2026 · Same journal
• EASIX and sC5b-9 for early identification of adults at high risk of developing TA-TMA after allo-HCT · Bone Marrow Transplantation · 2026 · Same journal
• Evaluation of a novel eHealth-facilitated, post HCT-integrated care model on implementation and rehospitalization: results from the Swiss SMILe hybrid-RCT · Bone Marrow Transplantation · 2026 · Same journal